Jasper Therapeutics Inc
JSPR
ISIN null / Valor 131966862
Jasper Therapeutics Inc
UMushroom community rating:
About company
Jasper Therapeutics Inc. is a biotechnology company specializing in the development of targeted therapies for chronic diseases by focusing on mast cells and stem cells. The company's primary investigational drug, briquilimab, is being evaluated for its potential to treat a range of conditions, including chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS). Additionally, briquilimab is being studied as a conditioning agent for stem cell transplants in patients with rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID). Jasper Therapeutics aims to advance innovative treatments that address significant unmet medical needs in these areas.
Summarized from source with an LLMView SourceSector: FinanceKey figures
Performance
Volatility
43 M
Market cap (USD)
472,042
Daily traded volume (Shares)
22.12 / 20.9
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Sabrina von Arx
EQUITIES OF THE SAME SECTOR
